Bristol Myers Squibb’s (BMS) next-generation antipsychotic therapy, Cobenfy (xanomeline and trospium chloride), has been shown to trigger improvements in hallucinations and delusions linked to Alzheimer’s disease – taking the drug in the right direction for a potential label expansion.
At the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, BMS presented positive findings from of two Phase III studies, ADEPT-1 and ADEPT-3, (NCT05511363; NCT05980949), in which researchers evaluated the longer-term efficacy and safety of Cobenfy for 12 and 52 weeks, respectively. BMS’ drug, also known in clinical development as KarXT, is already approved for schizophrenia.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new ADEPT-1 results stem from the 12-week open label portion of the study, while ADEPT-3 was specifically designed as an open label extension trial for patients who had finished treatment in ADEPT-1, 2 or 4.
In ADEPT-1, patients treated with Cobenfy on a three-times-daily dose experienced a mean 12.0-point reduction from baseline in clinician-reported hallucinations and delusions, on top of a 1.9-point drop from baseline in overall Alzheimer’s psychosis severity over the 12-week period.
Researchers observed similar positive outcomes in ADEPT-3, as Cobenfy prompted a mean 5.1-point reduction in hallucinations and delusions and a 0.8-point cut in overall disease severity from open-label baseline.
On top of its promising efficacy signals, patients generally tolerated Cobenfy well, with 4.4% of patients discontinuing treatment due to a drug-linked adverse event (AE) in ADEPT-1. Meanwhile, in ADEPT-3, 4.7% discontinued treatment following an AE.
Next steps for Cobenfy in Alzheimer’s
With these results now in hand, BMS will await results from the double blinded periods of the ADEPT trials, which could form the basis of Cobenfy’s marketing application in Alzheimer’s psychosis if positive.
BMS originally secured the rights to Cobenfy through its $14bn takeover of Karuna Therapeutics back in 2024. Since then, the drug has gone on to secure US approval for the treatment of schizophrenia.
However, BMS’s ambitions for Cobenfy do not stop there, as the pharma giant is also exploring the oral therapy’s potential across several neurological indications – including mania in bipolar I disorder, autism-related irritability and Alzheimer’s disease-linked cognitive impairment, psychosis and agitation.
In a recent Q3 earnings presentation, BMS noted that Cobenfy’s potential new indications will drive the next wave of growth within its neuroscience portfolio, despite a slow start to the drug’s launch due to tentativeness of prescribers and issues around access through insurance.
BMS progresses Cobenfy as the big pharma makes big changes to its R&D structure, with the company unifying its separate departments under a single entity from the beginning of 2027.
